 AUSTIN, Texas and DURHAM, N.C., March 09, 2022 GLOBE NEWSWIRE -- Shattuck Labs, Inc. Shattuck NASDAQ: STTK, a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that two posters have been accepted for presentation at the American Association for Cancer Research AACR Annual Meeting, which is being held April 8-13, 2022 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The first poster will highlight preclinical data from the companys GADLENTM platform, while the second will highlight preclinical data from SL-9258 TIGIT-Fc-LIGHT, derived from the companys ARC platform, demonstrating its ability to broaden the activity of checkpoint inhibitors through targeted myeloid cell and effector lymphocyte activation. 